{"schema_version":"1.0","type":"article","title":"Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug","url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html","markdown_url":"https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.md","lang":"en","date":"2026-06-05","publish_at":"2026-06-05T10:30:00+08:00","updated_at":"2026-06-05","category":"商業分析系列","topic":"臨床與 CMC","tags":["Clinical and CMC","Biotech business analysis","Drug development"],"summary":"Topical JAK drugs are not won by target biology alone. The real value lies in skin delivery, local exposure, systemic safety, indication choice, and whether the product can fit daily dermatology practice.","key_points":[],"facts":[],"sections":["Core Thesis","Why It Matters","Reading Framework","What To Watch Next","Original Chinese Edition"],"references":[],"images":[],"cover_image":"https://drugnews.com.tw/assets/english/drugnews-english-analysis-cover.png","publisher":{"name":"Drugnews｜藥時事","url":"https://drugnews.com.tw/","profile":"https://drugnews.com.tw/brand-profile.json"},"citation":"Drugnews｜藥時事（2026-06-05）。Starting With Ruxolitinib Cream: Why Not Every JAK Molecule Can Become a Topical Drug。https://drugnews.com.tw/articles/2026-06-05-topical-jak-inhibitor-skin-delivery-en.html","disclaimer":"This article is intended for industry research and knowledge sharing only. It does not constitute investment, medical, fundraising, or individual stock advice.","translations":{"zh-Hant":"2026-06-05-topical-jak-inhibitor-skin-delivery.html"},"relationship":"independent_editorial","disclosure_url":"https://drugnews.com.tw/policy/"}